Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi and Alnylam Amend Rare Disease Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Sanofi and Alnylam Amend Rare Disease Alliance

Concludes research and option phase of rare disease alliance, terms for patisiran, vutrisiran and fitusiran will continue unchanged

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi and Alnylam have concluded the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. The collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, will continue unchanged.
 
As part of this agreement, Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies and Sanofi will be responsible for any potential further development or commercialization. If this product is approved, Alnylam will be eligible to receive royalties on global sales.
 
“Our alliance with Alnylam has successfully brought one important medicine to patients with ATTR amyloidosis and it also has spawned a molecule that is in pivotal clinical trials for people with hemophilia,” said John Reed, global head of R&D at Sanofi. “As we wrap up this phase of our program with Alnylam, we remain committed to advancing therapies for patients with rare diseases and rare blood disorders.” 
 
In addition, Alnylam and Sanofi have agreed to amend certain terms of the companies’ equity agreement, with Sanofi obtaining a release of its lock-up of Alnylam stock holdings, subject to certain trading restrictions, and other provisions.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics